Analysis Published by PrecisionLife Reveals Potential to Systematically Reposition Hundreds of Patented Drugs into New Indications to Address Unmet Medical Needs • PrecisionLife’s unique combinatorial analytics approach to understanding the drivers of disease biology in patient subgroups has revealed hundreds of new commercial opportunities to reposition patented drugs and drug candidates into novel indications, with significant near-term additional revenue potential for pharmaceutical companies • Careful indication extension or repositioning of drugs coupled with patient stratification…

AMSBIO has expanded its range of top quality, high-performance assay kits, antibodies, enzymes, and substrates for cellular metabolism research. Cell metabolism is the series of chemical synthesis (Anabolism) and degradation (Catabolism) reactions of complex macromolecules, catalyzed by enzymes that take place in living organisms to sustain those organisms. Anabolism uses energy to make macromolecules (sugars, fatty acids, amino acids) and biomolecular polymers (polysaccharides, lipids, proteins). Catabolism releases energy when these are broken down into smaller molecules (carbon dioxide,…

The Enterprise Strategy from Anglia Innovation Partnership LLP will kickstart investment into new businesses at Norwich Research Park. Anglia Innovation Partnership LLP, the organisation that manages Norwich Research Park, has launched its Enterprise Strategy to kickstart investment into new businesses at the Park. Its aim is two-fold: to encourage those with a potential idea for a business – be they entrepreneurs or people studying or working at the Park – to come forward for support. It will also highlight to investors – whether venture capital companies or high net worth individuals – the…

Presenters will explain how long-term and whole-cell hepatocyte models can be used to improve in-vitro in-vivo correlation predictions and advance drug discovery and development research BioIVT, a leading provider of biospecimens, research models and services for drug and diagnostic development, today announced that it will host a symposium entitled “Innovative Models for ADME-Tox Research” at Hotel Odelya in Basel, Switzerland on June 22. “We are delighted to have this opportunity to meet with our biopharmaceutical colleagues in person,” said Jeremy Clarke, Senior Director of Business…

Polyspecific antibodies for cancer research AMSBIO announce a new range of high-quality bispecific antibodies (BsAbs) and trispecific antibodies (TsAbs) that can used to provide enhanced cancer therapeutic efficacy and/or safety compared to what can be achieved with conventional monospecific antibodies. The concept of using a molecule with more than one binding site to enhance its biological function has been around for some time. Polyspecific antibodies are the basis of a new class of anti-cancer agents which offer the potential to be directed at multiple tumor antigens to eradicate tumor…

AMSBIO offer an extensive range of aptamers targeting many human proteins linked to cancer. Aptamers bind to target molecules with the same affinity and specificity as antibodies but offer significant advantages, in particular a lack of immunogenicity, which makes them an ideal tool for cancer diagnosis and therapy. There are two major applications for aptamers in cancer therapy. Aptamers can be used as antagonists by targeting and inhibiting cancer-specific molecules. They can also be used as delivery vehicles for therapeutics by specifically targeting cell membrane receptors on cancer cells…

AMSBIO announce the launch of its StemFit Purotein® range of high purity, high activity recombinant proteins for cell therapy applications. Continued expansion of cell therapy applications across healthcare and the life sciences is driving a rapidly increasing need for clinically applicable ancillary materials. A key requirement is for recombinant proteins, such as growth factors and cytokines. This demand for clinically applicable recombinant proteins places stringent requirements on product quality, lot-to-lot consistency, and compliance with all relevant laws and regulations. All StemFit…

AMSBIO is a leading supplier of high purity exosomes using isolation methods including traditional differential and gradient ultracentrifugation, immunoaffinity, size exclusion chromatography as well as precipitation / low speed centrifugation. Exosomes are small endosome derived lipid nanoparticles actively secreted by exocytosis in most living cells. Release of exosomes occurs either constitutively or upon induction, under both normal and pathological conditions, in a dynamic, regulated and functionally relevant manner. Isolated from diverse cell lines, Exosomes have been shown to have…

In March 2021, the European Patent Office (EPO) Guidelines for Examination were updated to include a section devoted to the examination of antibody-related patent applications (Guidelines G-II, 5.6). This new section provided a much anticipated outline of the EPO requirements for different approaches to defining antibodies in patent claims (Guidelines G-II, 5.6.1) and helpful guidance in relation to the inventive step of antibodies in Europe (Guidelines G-II, 5.6.2). The new antibodies section of the EPO Guidelines was discussed in detail in our article “An antidote to antibody patent…

We have previously discussed the cell and gene therapy boom in the United Kingdom. The industry is thriving not only in the UK, but around the world, and here we take a quick look at some of the major successes and deals that have taken place in the last few months. Gene therapy deals As a quick reminder, gene therapy involves the transfer of genetic material, usually in a carrier or vector, into the appropriate cells for uptake of the genetic material. The vector can either be delivered outside the body (ex vivo treatment) where the targeted cells are removed from the patient and…